BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Milei Threatens Falkland Oil Firms With Sanctions 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Add as a preferred source on Google
BURLINGTON, Mass., Feb. 26, 2018 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its fourth quarter and full year 2017 financial results after the close of the U.S. financial markets on Thursday, March 8, 2018. Flexion’s management will host a conference call at 4:30 p.m. ET to discuss the results and provide an update on business operations.
The dial-in number for the conference call is 1-855-770-0022 for domestic participants and 1-908-982-4677 for international participants, with Conference ID #7699053. A live webcast of the conference call can also be accessed through the "Investors" tab on the Flexion Therapeutics website. A webcast replay will be available online after the call.
About Flexion Therapeutics
Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis. The company's core values are focus, ingenuity, tenacity, transparency and fun. Flexion was named one of The Boston Business Journal's 2017 Best Places to Work and one of the Top Places to Work in Massachusetts by The Boston Globe.
Contact:
Scott Young
Vice President, Corporate Communications and Investor Relations
Flexion Therapeutics, Inc.
T: 781-305-7194
[email protected]
